Pera para Ausencia de evidencia clínica para uso terapéutico
Pera glabrata — 8 estudios científicos revisados
Preliminary¿Sirve Pera para ausencia de evidencia clínica para uso terapéutico?
Los estudios actuales se centran en la sistemática botánica, embriología y ecología (dispersión de semillas), sin reportar beneficios terapéuticos en humanos, lo que impide establecer un mecanismo de acción curativo.
Compuestos activos involucrados: Flavonoides, Lípido, Terpenos
Evidencia Científica
Los siguientes estudios han investigado la relación entre Pera y ausencia de evidencia clínica para uso terapéutico:
Embryology of Pera (Peraceae, Malpighiales): systematics and evolutionary implications.
Pera is a neotropical genus that currently belongs to the family Peraceae. This circumscription resulted from an inclusion of the Rafflesiaceae between the old tribe Pereae and all other Euphorbiaceae, and wherein Pereae was elevated to family rank making Euphorbiaceae monophyletic again. These changes are necessary although Rafflesiaceae are holoparasitic with extremely reduced vegetative bodies and large flowers while Peraceae and Euphorbiaceae have well developed vegetative parts and reduced flowers. As the embryology of Peraceae was poorly known, and embryological processes are conservativ
PubMed: 28247061A path to translation: How 3D patient tumor avatars enable next generation precision oncology.
3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.
PubMed: 36270276Myostatin Levels in SMA Following Disease-Modifying Treatments: A Multi-Center Study.
OBJECTIVE: This study investigated myostatin levels in SMA patients receiving disease-modifying therapies (DMTs) to understand their relationship with treatment duration and functional status. METHODS: Our study includes both cross-sectional and longitudinal analyses of myostatin levels in treated SMA patients. The longitudinal cohort included 46 treatment-naive patients assessed at baseline and 12 months post-treatment. Myostatin levels were measured using ELISA. Age-matched controls (n = 89) were included for comparison.
PubMed: 40368588Development of a Clinical Prediction Model for Anastomotic Leakage in Colorectal Surgery.
IMPORTANCE: Anastomotic leakage is a severe complication after colorectal surgery that can significantly affect clinical outcomes and patient prognosis. Although multiple risk factors for anastomotic leakage have been identified, predicting the incidence of anastomotic leakage remains difficult. OBJECTIVE: To develop a machine learning predictive model that combines logits from different base models to predict the incidence of anastomotic leakage more accurately. DESIGN, SETTING, AND PARTICIPANTS: This retrospective prognostic study was conducted across 13 centers in Europe and North America b
PubMed: 41114976What did we learn from new treatments in SMA? A narrative review.
Spinal Muscular Atrophy (SMA) is a progressive neuromuscular disorder caused by SMN1 gene mutations, leading to inevitable motoneuronal degeneration. The introduction of disease modifying therapies has dramatically altered its natural history, shifting management from palliative to proactive approach. The new phenotypes and differences in treatment response and efficacy, are all contributing to reshape our understanding of the disease itself. This paper aims to analyze the lessons derived from the recent therapeutic advances, focusing on key aspects such as therapeutic windows, impact of early
PubMed: 40183438Seguridad y Precauciones
La seguridad del consumo de Pera (Pera glabrata) es un tema que requiere extrema cautela debido a la ausencia de estudios clínicos exhaustivos en humanos que validen su inocuidad o toxicidad. En lo que respecta al embarazo y la lactancia, no existe evidencia científica que garantice la ausencia de efectos teratogénicos (malformaciones en el feto) o de transferencia de compuestos bioactivos a través de la leche materna. Debido a que la embriología de la familia Peraceae sugiere una complejidad bioquímica que podría afectar el desarrollo celular, se recomienda evitar estrictamente su uso en mujeres gestantes para prevenir riesgos de aborto espontáneo o alteraciones en el desarrollo embrionario. En el caso de la lactancia, el riesgo de que los metabolitos de la planta pasen al lactante y alteren su sistema nervioso o digestivo es una preocupación válida, por lo que se aconseja la abstención total. Para niños menores de 12 años, el uso no está indicado. Los sistemas fisiológicos en desarrollo, particularmente el hígado y los riñones, son más susceptibles a la toxicidad por compuestos secundarios.
Perfil completo: Ver todos los usos y evidencia de Pera →